Alnylam Pharmaceuticals, Inc: Dodge & Cox Makes Purchase .

Infectious disease

531 Views

        

February 10, 2018 - By Marguerite Chambers

 Alnylam Pharmaceuticals, Inc: Dodge & Cox Makes Purchase

Investors sentiment decreased to 0.92 in Q3 2017. Its down 0.60, from 1.52 in 2017Q2. It is negative, as 30 investors sold Alnylam Pharmaceuticals, Inc. shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. 86.02 million shares or 0.72% more from 85.40 million shares in 2017Q2 were reported.

Schwab Charles Invest Management Inc, California-based fund reported 244,550 shares. Florida-based State Board Of Administration Of Florida Retirement has invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Moreover, Prudential Fin has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 4,504 shares. Aperio Grp Ltd Liability Corp invested in 0.01% or 16,908 shares. 31,897 are owned by University Of Notre Dame Du Lac. Proshare Advsr Lc owns 53,478 shares for 0.06% of their portfolio. Advsrs Asset reported 0.03% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Wellington Mgmt Gp Llp accumulated 0.3% or 11.30M shares. Moreover, Rock Springs Capital Mngmt Lp has 0.57% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 105,000 shares. Artal Gp holds 0.51% or 250,000 shares. Bb Biotech Ag holds 3.61% or 1.11M shares. Fmr Ltd Com invested in 13.76M shares. Grp Inc One Trading L P holds 0.07% or 68,743 shares. M&T Natl Bank reported 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Arrowstreet Capital Ltd Partnership holds 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 51,485 shares.

Since September 20, 2017, it had 0 insider purchases, and 3 sales for $23.18 million activity. On Monday, October 2 the insider Greene Barry E sold $10.66 million.

The New Dodge & Cox Holding in Alnylam Pharmaceuticals, Inc

Dodge & Cox reported SC 13G/A form with the SEC for Alnylam Pharmaceuticals, Inc. Access it here: 000119312518037988. As reported by Dodge & Cox, the filler owns 8.3% or 8,231,595 shares of the Health Care–company.

Alnylam Pharmaceuticals, Inc stake is new for [reportingPerson]. Date of activity: December31, 2017. This shows Dodge & Cox’s positive view for Alnylam Pharmaceuticals, Inc. For a institutional investor managing $224.00 billion in assets and having 205+ experts this is interesting position.

Alnylam Pharmaceuticals, Inc Institutional Sentiment

Filings show 240 investors own Alnylam Pharmaceuticals, Inc. The ownership in Q3 2015 is very high, at Infinity of the outstanding shares. This is increased by 11263456. 75993542 were owned by these investors. 36 funds opened new Alnylam Pharmaceuticals, Inc stakes, 89 increased positions. There were 52 that closed positions and 83 reduced them.

7 investors had the stock in their top 10. Some are: Fic Capital Inc, Pdt Partners Llc, Perceptive Advisors Llc, 12 West Capital Management Lp, Emory University, Opus Point Partners Management Llc, 683 Capital Management Llc, Gilder Gagnon Howe & Co Llc..

David Greenspan Slate Path Capital Lp is an investor bullish on Alnylam Pharmaceuticals, Inc, owning 595000 shares as of Q3 2015 for 5.48% of its portfolio. 12 West Capital Management Lp owns 651000 shares or 7.63% of its portfolio. NY Fic Capital Inc have 6.12% of its portfolio for 162117 shares. Further, Rtw Investments Llc reported stake worth 13.32% of its portfolio. The NY Tocqueville Asset Management Lp owns 110345 shares. Alnylam Pharmaceuticals, Inc is 0.12% of its portfolio.

Business Profile

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company’s lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

SEC Form 13G.

Dodge & Cox website.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 14. They expect $-1.40 earnings per share, down 6.06 % or $0.08 from last year’s $-1.32 per share. After $-1.34 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 4.48 % negative EPS growth.

The stock decreased 0.34% or $0.4 during the last trading session, reaching $115.92. About 1.30 million shares traded or 18.27% up from the average. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since February 11, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $11.50 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals has $220 highest and $34 lowest target. $123.52’s average target is 6.56% above currents $115.92 stock price. Alnylam Pharmaceuticals had 95 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, January 8 by FBR Capital. The firm earned “Buy” rating on Thursday, June 22 by Jefferies. TheStreet downgraded the shares of ALNY in report on Saturday, August 22 to “Hold” rating. The rating was maintained by FBR Capital on Friday, February 2 with “Buy”. On Tuesday, May 3 the stock rating was maintained by Leerink Swann with “Outperform”. On Friday, February 9 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. Cowen & Co maintained the stock with “Buy” rating in Friday, August 4 report. The firm earned “Mkt Perform” rating on Thursday, October 6 by Leerink Swann. The firm has “Hold” rating given on Thursday, October 6 by Stifel Nicolaus. The rating was maintained by Credit Suisse with “Outperform” on Friday, November 3.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Medicines Company continues inclisiran-stoked rally, shares ahead 8%” on January 24, 2018, also Fool.com with their article: “Will 2018 Be Alnylam Pharmaceuticals, Inc.’s Best Year Yet?” published on January 14, 2018, Businesswire.com published: “Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial …” on February 08, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Marketwatch.com and their article: “Alnylam Pharma loss widens as costs rise” published on February 08, 2018 as well as Gurufocus.com‘s news article titled: “Xact Kapitalforvaltning AB Buys Alnylam Pharmaceuticals Inc, The Chemours Co …” with publication date: February 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.